Cue Biopharma, Inc.
CUE
Rank in Stocks
#18040
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on... Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various cancers, chronic infectious diseases, and autoimmune disorders. The company's leading investigational therapeutic is CUE-101, a specialized fusion protein biologic. This candidate is currently advancing through Phase 1b clinical trials, engineered to specifically identify and activate antigen-specific T cells involved in cancers originating from human papillomavirus. Beyond its flagship program, Cue Biopharma is also developing a range of other innovative platforms: CUE-102, another fusion protein biologic designed to stimulate specific T cells to combat cancer; CUE-103, an Immuno-STAT from the CUE-100 series, which is developed to target the KRAS G12V mutation relevant in diseases like colorectal, lung, and pancreatic cancers; CUE-200, which concentrates on cell surface receptors such as CD80 and/or 4-1BBL to counteract T cell exhaustion often seen in chronic infections; and the CUE-300 and CUE-400 frameworks, conceptual platforms aimed at treating diverse autoimmune conditions. Cue Biopharma maintains key strategic alliances, including collaborations with Merck Sharp & Dohme Corp. for the research and development of its unique biologics targeting autoimmune indications, with LG Chem Life Sciences for advancing Immuno-STATs in the field of oncology, and with the Albert Einstein College of Medicine. The company, founded in 2014, was initially known as Imagen Biopharma, Inc. before adopting its current name, Cue Biopharma, Inc., in October 2016. It is headquartered in Cambridge, Massachusetts.
Share Price
$20.14
Last synced: 2026-11-09
Market Cap
$146.31M
Change (1 day)
7.53%
Change (1 year)
-1.71%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Cue Biopharma, Inc. (CUE)
Category
Healthcare
Operating Margin for Cue Biopharma, Inc. (CUE)
Operating Margin as of November 2026 TTM: -261.97%
According to Cue Biopharma, Inc.'s latest financial reports, its current operating margin (TTM) is -261.97%. At the end of 2025 the company had an operating margin of -96.56%.
Operating Margin history for Cue Biopharma, Inc. from 2015 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -261.97% | 171.30% |
| 2025 | -96.56% | -78.39% |
| 2024 | -446.86% | -52.96% |
| 2023 | -949.89% | -77.78% |
| 2022 | -4,275.10% | 1,361.27% |
| 2021 | -292.56% | -79.51% |
| 2020 | -1,427.96% | 34.31% |
| 2019 | -1,063.21% | -68.61% |
| 2018 | -3,386.71% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.15% |
US
|
|
| -149.01% | -99.43% |
US
|
|
| 25.57% | -100.10% |
AU
|
|
| 31.23% | -100.12% |
BE
|
|
| 29.35% | -100.11% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Cue Biopharma, Inc.'s operating margin
What is Cue Biopharma, Inc.'s operating margin?
Cue Biopharma, Inc.'s operating margin is -261.97%, as of Nov 2026.
What was Cue Biopharma, Inc.'s operating margin in 2025?
In 2025, Cue Biopharma, Inc.'s operating margin was -96.56%, compared with -446.86% in 2024.
How has Cue Biopharma, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Cue Biopharma, Inc.'s operating margin was highest in 2025 (-96.56%) and lowest in 2022 (-4,275.10%).
How does Cue Biopharma, Inc.'s operating margin compare with similar companies?
Cue Biopharma, Inc.'s operating margin (-261.97%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.